Login to Your Account



Xenova Shares Fall On News Of Ended Millennium Alliance

By Aaron Lorenzo


Wednesday, November 17, 2004
Xenova Group plc is losing a partner for its DNA-targeting oncology program. The Slough, UK-based company said Millennium Pharmaceuticals Inc. would no longer fund the program after the end of ongoing Phase I studies of XR11576 and XR5944, a decision made following an internal portfolio prioritization review. Millennium has been Xenova's North American partner for the program for three years. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription